Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| XRX | 8-K | bearish | 7/10 | Xerox reported Q3 2026 revenue of $1.87B, down 4.7% YoY, and a GAAP net loss of $(1,015)M driven by a $959M goodwill imp | Oct 29, 2026 |
| AAMI | 8-K | bullish | 6/10 | Acadian Asset Management reported Q3 2026 results with record quarterly management fees of $187.8M, up 38% YoY, and ENI | Oct 29, 2026 |
| ARXS | 8-K/A | neutral | 4/10 | Arxis, Inc. filed this 8-K/A to provide the audited and unaudited financial statements of Omnetics Connector Corporation | Oct 29, 2026 |
| BCBP | 8-K | bearish | 6/10 | BCB Bancorp reported a Q3 2026 net loss of $132.5M ($6.92 per share), driven by a $115.0M provision for credit losses an | Oct 29, 2026 |
| NUR | SC 13G | neutral | 4/10 | KW Capital Partners Ltd. filed a Schedule 13G disclosing a 7.2% passive stake in Nuran Wireless Inc., representing 945,5 | Oct 29, 2026 |
| VBIO | 8-K | neutral | 3/10 | Valion Bio announced positive safety results from a government-funded preclinical study of its lead drug candidate Entol | Oct 29, 2026 |
| KPRX | 8-K | bullish | 6/10 | Kiora Pharmaceuticals in-licensed exclusive rights (outside Asia) to KIO-401 (mitucapistat), an oral calpain inhibitor t | Oct 29, 2026 |
| OPEN | 8-K | neutral | 2/10 | Opendoor appointed Michael Alfred, founder of Alpine Fox LP, to its Board of Directors and the Nominating and Corporate | Oct 29, 2026 |
| SAIA | 8-K | neutral | 5/10 | Saia reported record Q3 2026 revenue of $982.5M (+17.0% YoY) and GAAP diluted EPS of $3.41, compared to $3.22 in Q3 2025 | Oct 29, 2026 |
| BTQ | 6-K | neutral | 3/10 | BTQ Technologies announced that its MIMIQ quantum emulator, developed by wholly owned subsidiary QPerfect, is now availa | Oct 29, 2026 |
| CDLR | SC 14D-9/A | neutral | 5/10 | Cadeler A/S filed Amendment No. 2 to its Schedule 14D-9, confirming that the exchange offer by Cadeler plc (NewCo) expir | Oct 29, 2026 |
| HGV | 8-K | bearish | 6/10 | HGV reported Q3 2026 adjusted diluted EPS of $4.03, far above the $1.11 consensus, but the beat was driven by a $296 mil | Oct 29, 2026 |
| SFL | 6-K | bullish | 5/10 | SFL Corp announced agreements to acquire two 8,800 TEU container vessels (delivery 2027) and one 93,000 cbm dual-fuel Ve | Oct 29, 2026 |
| NAVI | 15-12G | neutral | 5/10 | Navient LLC filed a Form 15-12G to terminate the registration of its common stock under Section 12(g) of the Exchange Ac | Oct 29, 2026 |
| GBC | 424B4 | neutral | 5/10 | Georgia Banking Company, Inc. filed a final prospectus (424B4) for the resale of up to 7,074,016 shares of common stock | Oct 29, 2026 |
| CRH | 8-K | bearish | 6/10 | CRH reported Q3 2026 revenue of $11.4B (+3% YoY) and GAAP diluted EPS of $1.86, below the consensus estimate of $2.03. N | Oct 29, 2026 |
| VRAX | 6-K | neutral | 3/10 | Virax Biolabs announced non-exclusive distribution agreements with three Chinese distributors for its ImmuneSelect resea | Oct 29, 2026 |
| INMB | 8-K | bearish | 6/10 | Inmune Bio entered into a securities purchase agreement for a registered direct offering of 3,000,000 shares at $1.50 pe | Oct 29, 2026 |
| DQ | 6-K | bearish | 5/10 | Daqo New Energy reported Q3 2026 revenue of $194.2M, well above the $65.0M consensus, and a GAAP net loss of $52.9M ($0. | Oct 29, 2026 |
| CART | 8-K | mixed | 9/10 | The release was overshadowed by the simultaneous announcement of a definitive agreement to be acquired by DoorDash for ~ | Oct 29, 2026 |
| MNRO | 8-K | bearish | 5/10 | Monro reported Q2 fiscal 2027 results with sales down 1.8% to $283.6M and a net loss of $1.6M versus net income of $5.7M | Oct 29, 2026 |
| CDLR | SC TO-T/A | mixed | 7/10 | Cadeler plc (NewCo) filed Amendment No. 2 to its Schedule TO, reporting that as of the October 28, 2026 expiration, 355, | Oct 29, 2026 |
| ATI | 8-K | bullish | 6/10 | ATI reported Q3 2026 results with sales of $1.42B (up 26% YoY) and GAAP EPS of $1.37 (up 76% YoY), exceeding the high en | Oct 29, 2026 |
| HLN | 6-K | neutral | 3/10 | Haleon announced a GBP 500 million share buyback programme, to be executed by Citi on the London Stock Exchange, CBOE Eu | Oct 29, 2026 |
| RXO | 8-K | bullish | 6/10 | RXO reported Q3 2026 adjusted EPS of $0.09, beating the $0.07 consensus, and revenue of $1.87B, above the $1.82B consens | Oct 29, 2026 |
| DTM | 8-K | bullish | 6/10 | DT Midstream reported Q3 2026 net income of $118M ($1.16 per diluted share) and Adjusted EBITDA of $301M, with year-to-d | Oct 29, 2026 |
| PHIN | 8-K | bullish | 6/10 | PHINIA reported Q3 2026 net sales of $912M (flat YoY excluding FX) and adjusted EPS of $1.83, beating the $1.68 consensu | Oct 29, 2026 |
| CQP | 8-K | neutral | 5/10 | Cheniere Energy Partners reported Q3 2026 revenue of $2.574B (up 7% YoY) and GAAP net income of $0.639B (up 26% YoY), wi | Oct 29, 2026 |
| CDLR | 6-K | neutral | 5/10 | Cadeler A/S announced preliminary results of its share exchange offer by Cadeler plc, with a 92.02% acceptance rate, in | Oct 29, 2026 |
| NUAI | PRESS-RELEASE | bearish | 5/10 | New Era Energy & Digital announced a PIPE raising approximately $64 million through the issuance of 23,272,727 shares at | Oct 29, 2026 |